Significant efforts have been made to identify new pancreatic cancer-associated antigens, preferably shared by the majority of patients, such as carcinoembryonic antigen (CEA)[10], mucin-1 (MUC-1)[10] and the product of mutated KRAS[10], to develop targeted vaccination strategies. This evidence concerns the gene MUC1 and familial pancreatic carcinoma.